drugset / Trial / NCT03786289

Study on Single Administration and Dose Increment of Recombinant Human Serum Albumin/Erythrocyte Fusion Protein for Injection

NCT03786289

Phase 1 Completed 34 enrolled Tianjin SinoBiotech Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study was to evaluate the safety of rHSA/EPO to healthy subjects and to investigate the pharmacokinetic characteristics of rHSA/EPO in healthy subjects, and to obtain preliminary pharmacokinetic parameters.

Timeline

Start
2018-12-03
Primary completion
2019-07-03
Completion
2019-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED Protein / enzyme biologic 150 ug Subcutaneous
Subject HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED Protein / enzyme biologic 1200 ug Subcutaneous
Comparator epoetin alfa Protein / enzyme biologic 10000 iu Subcutaneous

Indications

No indication recorded.